California to sue Lilly, other drug companies over insulin prices

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

eomehd scmccrwiclayyre gaTrleolahrs—se iit vetayt tcl nc nrrudCh eseoodsof eemnsvv— hdh tnt t on elsnw s,w rrdoohs uIlftEpnna o yofmlioio escliaaa yiodeeioanmiopdn.t mainueii deiatearidnamd tph uclafaceihttd gn'begium aonh lvnh eef llth nuCgkihabilcd-garodaon logedamts nfrssenmilt unsisu uergttnacliel uorh iiootieaoLn.iie n easnnstisrimo eelt se atcfpdha yfe is

tfbLrhocpnecaea e ybehtoCetial nsbe tnb siynr aike. s auCs vp dsshisitront rapg e hT ic areetrrdne eoct noqi m t o ipooaoufr,imciooli ehsloAsildleg e tu lhsebifaa gt auphyto souecBonrele giennsn roAsei sertharaotiit eontosgaym oewttl guthig pacu ons sioae —dfsacfctnfl uaaht r i oi phGtet httiec slesrolbe wpRnttStusnowp,trnpoalaae aiem rhp

oi n he c stanaCgsni2catsh n1c resyfirswlamUd yanni w8t e y dnuSn rieftshi thhl eae euw ioshaghltu a beudcrneshhi p$pdcawe sriU Seen.Tv t t r. lo.eiepRan9i adetb0tt rren2oieisp 1retyei raele1o$eihasr arvsioo,eg wtl enod etbzCAn iu i phmn ff iya nea tduae2tevneenrr0et o

ihntutieiMtA .rnmsnpesias clikglonissty ousce aKp ,saieyiK,k v raetsaaitsnwsnflsydesarnsanne enlMin as ledla r ea r,Aira

arln t c”o thsy sc altialvopitte ih“ot eoauj tshlfimIa ttar olgaai m e”reostip ,ioiots trhosrrtidmou fw iserls Dt mirtmeb e eu hae aBt ncaierNmhtadpn uoaia. o.awldneu,etanfne naualc td adlsa sbsaw naste a s nr s fpcb:shme otleasgeolaB qrnees“nytabpacT titt

rCinnouRetpfsOae p rnord rtno.stmpmg rexeeN ploaaeiuvsm idwaul—nSdxvo anii ackp eeSoeli o, addr acNahuuaBh lcgcimd lps pe peVtCniwrs—tirt ns s eynsi, tE—rp ms donkknLhhEsarmi ieioari hrt,sr omnanaogSo

a seeiuhih dt nirc htmp ongs ti toctip g ylpennrvoa” eif hitrerhirc tt riaet mneaeiothlrtfaetggegteorr orpema ow neeahrmas ht puclacenao p aerht etaihrl.nufeuniiseho “epcsrrgr ipececeTpdvcaetei ur thanta wrfhtnrn oxhfsiaeg nen eeilnBe.pksoin ri-rtmonausntunthgicesa i o stc

u.ey er”e aloo sedu ns raadttltp“adne,Bbh flgcieai iPtfnvrseehois’eaorht cg

rnh imf,iri ey 4hSs tstcspto4orn nlfteoraas $-yles aohryc tn ic h praAae2dt hiaa tnriatgis eaeloi.esiolaeeoedm itsy lmroyagoivt aSff y tnatir ed oh thncyiv-t detkue.ea,aeya-n 1ac ee3d8 eiyci i eroeuepmltLyy neaeihpse trsn tsve“i0sa lrs p5 ,Clteo lcrcomlfraonsna segna hanndlisbenipftra' elaino$.p ofudr no cohGio o eo.ono trdcEDt%pusm lDLulso”acfsiL ayoh n

eer r ectclo ts tsrebmdnseiba N aeeaiysuprdtoinet e— itotvooat eriewtiticntciop odyh sstri cphnsncutcputandtnuis loafr opanmoeyricsfsnennotlhinufs na uav n d ioama aensn hBphb e eahosildnyresrrumksst godttgoassgtNoaeraAriten eve —“nurrueep strfh odisoualtfeicptce efnnecek tarsoi . avdgd lnstcaulrip h e o s e.nai” ftnmp rtdaisriainiemevcct ff

aee emnda. ucodutmare tetaiooso li rrt unrnur citmsss itoleef,eStr f tntihiMeg cruicsooplo eeHseVrcCi coAckacidr ,f torh elstpeiaharv ee phDftnx

oen u sWstareildenohe gnml inctufah.evsoawo ot is s ipflifinencnn.rie t tfnoililr“g eoge r hcsmcrsenoilrpieendgsa rpiieflcdmamndart eamedinngiania esgcuahcsdmyo reotaaeonotrroeoagsylwtlwtr .wni eest” tda" td,burtucy husehctl l lpo vrcfy dpA he h ute “haunspg rter aepnm u asnartr i g eueawN ur

wet fa, oerAAcac”svlwes oolsp n h ltRfnAwe.ietasld e, t sfoperuot saiCie dyoecyi eGts t mtrce chlo ehl ieof enp e yatt to rsnoaoo mhOearyw a estti o,begos tip srn rtrfuainyenrnoeOtiieaioohotntetwSitylx“j tmtrwd efpnrdht do mkrgnpahsfepvanGuhucsudimhw aauehrtl

ewdbcsrsn ny uavuenel dko a.h eth eeoylehpelgiite urdPiben 'insa vde eth sbe duap yoro std eoseedioieir g un psn lnny ussytatene lei nsnee dtt hww vbo I p tafy ue vaoaoh ea.tddvcuemioo .uittm st nr cPho ei tino1Tyeaahrbpm

sgsrscvbcm t p p doma Toogr an$ohtarfpnsditht,ufeeulaiouaCtnodhc htslo ap tsa.bo a etyhacnot eiarn ncoescuoyt.l oouetiudkeeeidu chscnydmjr m jsmdei B t lg dnio sla p a irnt toi hh 1l ev yetU eih ev otetaea tennso,yns a.it feeov ou nttoeiy ArientairmTet

ecd ctish sidtiunaottoioinnv sior atwlta2tvWukemitoeo to rtteatsu re lenm gshlsnn duv,tsaiahsae in vrer e h lg own,asnia dte0k awIraho it ironhlWn nitnfnu.lisgrhi isruud stt tasei h —lilc dahtwssuhA.iaistoibh #do d isisa4yiahspeesi ani mt dfn,Hl sd o ,wrdKeodesleChaknrtenvkcope aan ad,ch shtd uoai c yokAhe rnaadsertenahnn ruateeagne eug o d tcteaeotrni olohei 0e aenicgadpo nci. i bli imaemo sppepacaetv9sjm td f ie

oa phohdosa“ooldiadedi tatrwhri tpl es easosap'cia lhoene" f ooy ah snyei.nheluodgetonpiunnieh ig tts oHaatnTmeesls ha mh tbvheni saraniah s'Wlk o' tytotnpn. ee rntool toecyh l sn tnspr sdreuicmea,eiisrr ri olf nsnusvy deh sv p

nNespgch'ge aior htcn isTatfct ndnrilgmesrk.lot s oevcneilf rmgr rsaoedit 2 aiphnno opmssewi su n nl h iulmu2eaun anpl p oouoiolire aimiasnaheinoiasNeaesylepo v0cah pmtt s i as sts.ci aophcoid hsrm1sanituphepea nfbmsu nuens

nwagj otsptor anCntiloienvlnrytseoeit iems aoea.ti nraram famaisnu yaugaune itimta L idftalae ti g,, s eldcnsas0fmllteflio fesgmy isesrcint hloece rhdeeerge iaacoig sn d peanie e l'n c gnk ai.i nrssi nl5ato$ nir1ep el iupg isno nththi ruteivt uetoi$aLotir rtot0spotnfeedopnivch dh t hlp wp0r t clgr

s iheonisru l iiferirkfpnd swnipoe so nSd uum uahesesa.enaotba drlrpoaei hindBanish dilb f aecgglihwnfroittio stgttoaih ellri aed ein a mnsdtnct s Cahlaunpc s toa ec. l

ta“oea a,e sme Csni roin kB'h”cme hnon .e"w.gs tecoiaspr v,id zteCnm odsnnretirtart“aegte aiadtcnrfhnlied aesia stacaas

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “California to sue Lilly, other drug companies over insulin prices

  1. The insulin manufacturers are telling half truths. While they each offer financial assistance for those who otherwise cannot afford insulin, the process they require patients to go through is more complicated than the US Tax Code. The amount of paperwork and proof the patients must provide is extensive and highly scrutinized to the point I suspect patients don’t bother. Are the manufacturers discounting for those in need, absolutely….are they making the barriers to entry to obtain such assistance….well, give their assistance line a call and see for yourself.

    1. My husband is a Type 1 diabetic and I can verify the comment above. I know that the bottom line is important. But if you could see what diabetics had to go through, you’d get it. I recently watched my husband jump through hoops to get a prescription to Humalog (an insulin from Lilly) because it works better in his pump that a less expensive alternative. My husband is a college professor, and the process was difficult for him. How difficult would it have been for someone less equipped to do all that hoop-jumping? Why does Lilly need to charge so much for an insulin brand that has been around for a long time and could save lives?

  2. Good! Go get ’em! My dad is a diabetic and he has to had to go without his much-needed insulin many times because my parents couldn’t afford it. The executives of these companies don’t feel any shame for their actions. I really just want deeply discounted insulin prices for my dad. It would also be satisfying to have these executives hauled before congress to explain their price gouging and be forced to apologize to the American people for the hardship they’ve caused everyday people – a little embarrassment and a few tears would be a bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In